In this context, the conclusion drawn from the work of Terlizzi et al. [14] that pharmacological inhibition of caspase 8 reduces tumor growth by reducing the release of pro-inflammatory cytokines seems especially interesting because it suggests that the initial genotype that conditions high expression may lead to worse prognosis in NSCLC. This evidence concerns the gene CASP8 and neoplasm.